After the approval of immune checkpoint inhibitors, overall survival among US patients with advanced-stage cancer improved, but disparities between uninsured and privately insured widened.

Panelists discuss treatment considerations for metastatic melanoma with high tumor burden, highlighting the preference for immune checkpoint combinations like nivolumab with relatlimab for durable ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

Results of a phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax ...

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called ...

Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, ...

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.

A high-fiber diet may improve response rates and event-free survival outcomes in patients with advanced melanoma receiving standard immunotherapy.

Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients with MSI-H/ dMMR metastatic colorectal cancer.

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma ...